Shopping Cart
Remove All
Your shopping cart is currently empty
Guanethidine sulphate, synthesized in 1959, is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 mg | Inquiry | 6-8 weeks | 6-8 weeks | |
| 500 mg | Inquiry | 6-8 weeks | 6-8 weeks |
| Description | Guanethidine sulphate, synthesized in 1959, is thought to lowing blood pressure by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres. |
| In vitro | Sympathetic fibers ablation is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro [1]. |
| In vivo | Guanethidine (30 mg/kg, s.c., 1 h) administration does not alter IL-18 induced hypernociception in TNFR1 (-/-) mice, indicating that this sympathetic blocker is ineffective in this context [2]. This outcome was observed in a study involving WT Balb/c, TNFR1 (-/-), and IFN-γ (-/-) mice, with guanethidine diluted in saline. |
| Molecular Weight | 198.31 |
| Formula | C10H22N4 |
| Cas No. | 55-65-2 |
| Relative Density. | 1.13g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.